Vimarsana
Biggest News Aggregation in the World

Page 2 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sciences Group Today - Breaking & Trending Today

Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. - Vimarsana News

Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.

Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. These Common Stock will be under lockup for 61 days starting from 19-MAR-2024 to...

Business owner charged with fraud in $8M deal for face masks - Vimarsana News

Business owner charged with fraud in $8M deal for face masks

Julie Dotton faces a criminal charge of wire fraud after convincing a Montreal company to pay $8.2 million up front for millions of face masks she offered to deliver in

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease - Vimarsana News

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.

Earth Day celebration returns to Redstone Arsenal - Vimarsana News

Earth Day celebration returns to Redstone Arsenal

The Team Redstone Earth Day/Arbor Day celebration on April 25 will feature tree giveaways, food trucks and a variety of exhibitors and on April 25 and 26, you can pitch

SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study - Vimarsana News

SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study

SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on cancer, announced Tuesday positive topline data from the Phase 2a study of SLS009 in relapsed or refractory acute myeloid leukemia or r/r AML.